This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Core Lab & Long Read Sequencing/Short Read Sequencing July 2024

Ticker(s): TMO, ILMN, PACB, BNGO, ONTTF

Who's being surveyed?

The survey includes 20 respondents currently using DNA technologies.

Survey Questions
Q1.

Do you use DNA sequencing technologies in your practice?

Q2.

How would you best describe your practice?

  • Academic
  • Community
  • Commercial
  • Other


Q3.

Rank the factors that influence your choice of DNA sequencing technologies in your practice (where 1 is the most influential and 5 is least influential). Please rank all.

  • Accuracy
  • Cost
  • Ease of use
  • Read length
  • Throughput

Q4.

Do you use short-read sequencing technologies?


Q5.

What is the percentage breakdown/distribution of short-read sequencing technologies you currently use?

  • Illumina (e.g.,NovaSeq, HiSeq, MiSeq, etc.):
  • Thermo Fisher Scientific (e.g., Ion Torrent, Ion GeneStudio, etc.):
  • Oxford Nanopore Technologies (e.g., Flongle, Rapid Barcoding Kit):
  • Other:

Q6.

What is the percentage breakdown of short-read sequencing technologies you expect to use in 1 year?

  • Illumina (e.g.,NovaSeq, HiSeq, MiSeq, etc.):
  • Thermo Fisher Scientific (e.g., Ion Torrent, Ion GeneStudio, etc.):
  • Oxford Nanopore Technologies (e.g., Flongle, Rapid Barcoding Kit):
  • Other:

Q7.

Please elaborate if you indicated "Other" above. If "Other" is 0, please indicate "NA".

Q8.

What are pros and cons of Illumina's short-read technologies? Please be specific.

Q9.

What are pros and cons of Thermo Fisher Scientific's short-read technologies? Please be specific.

Q10.

What are pros and cons of Oxford Nanopore's short-read technologies? Please be specific.

Q11.

Do you currently use long-read sequencing technologies?

Q12.

What is the percentage breakdown/distribution of long-read sequencing technologies you currently use?

  • PacBio (e.g., Sequel lle, RS II, etc.):
  • Oxford Nanopore Technologies (e.g., MinION, GridION, PromethION, etc.):
  • Bionano Genomics (e.g., Saphyr system):
  • Other:

Q13.

What is the percentage breakdown/distribution of long-read sequencing technologies you expect to use in 1 year?

  • PacBio (e.g., Sequel lle, RS II, etc.):
  • Oxford Nanopore Technologies (e.g., MinION, GridION, PromethION, etc.):
  • Bionano Genomics (e.g., Saphyr system):
  • Other:

Q14.

What are pros and cons of PacBio's long-read technologies? Please be specific.

Q15.

Please elaborate if you indicated "Other" above. If "Other" is 0, please indicate "NA".

Q16.

What are pros and cons of PacBio's long-read technologies? Please be specific.

Q17.

What are pros and cons of Oxford Nanopore's long-read technologies? Please be specific.

Q18.

What are pros and cons of Bionano Genomics' long-read technologies? Please be specific.

Q19.

Do you currently use hybrid sequencing technologies?

Q20.

As competition grows within the space, are you contemplating a switch from Illumina to any of its competitors (e.g., PacBio, Singular Genomics, Element Biosciences)? Please elaborate why or why not.

Q21.

What barriers, if any, have you noticed in adopting DNA sequencing technologies in your practice?

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.